跳至主要内容
临床试验/IRCT20200517047485N1
IRCT20200517047485N1尚未招募3 期

Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19

Arak University of Medical Sciences0 个研究点目标入组 108 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
108

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Patients who are hospitalized in the ward and are considered to have a moderate form of COVID-19 (need to be admitted to the ward and not ICU hospital)
  • Patients who are satisfied with the study entry

排除标准

  • The patient has a severe disease that requires Ribavirin
  • The patient need to be hospitalized in the ICU or intubation
  • The patient has a mild form of the disease that does not require hospitalization (patients with a history of outpatient treatment for COVID-19).
  • Patients with specific underlying disease and / or need to take specific medications

研究者

相似试验